

Gavi 5.0: An Overview of Key Issues

BOARD MEETING


Anuradha Gupta, Deputy CEO

28 September 2021, Virtual Meeting




Gavi 5.0 begins amid reversal of gains and continued uncertainty

Number of children immunised




- Gavi 4.0 target exceeded: **324m children immunised**
- **>580m people** additionally reached through **campaigns**
- **Number of children immunised with DTP3 declined** from 65.5m in 2019 to 63m in 2020

Routine coverage (DTP3)




- 2015-2019: **DTP1, DTP3 and MCV1 increased by 3pp** after a period of stagnation with **14% reduction in zero dose children**
- **4pp decline in DTP1 & DTP3**, and 3pp decline in MCV1 in 2020
- Immunisation **decline less** than many other essential health interventions

Breadth of Protection



- After 4 years of rapid scale-up, **vaccine introductions slowed down** in 2020 and **HPV coverage took a hit** with coverage at just 8%
- Despite 2020 set-back, **coverage is higher in Gavi-supported countries** than rest of the world for PCV, Rota & Hib

Repercussions of the pandemic are still unfolding with variable impact on immunisation across countries



Reflecting 40 Gavi68 countries with reporting through June 2021, accounting for 54% of the surviving infant population

Disruptions appear to be less


severe in first half of 2021 compared to Q2 2020, though still uncertain as fewer countries reporting

Recent data showing continued regional variability, with **Asia seeing largest disruptions**

Data for India not reported for full Q2 2021, accounts for 29% of Gavi-supported birth cohort







Health systems in Gavi countries preparing for a 3-fold increase in vaccination touchpoints for COVID-19 vaccines

- In second half of 2021, expect **>3 times** more vaccination touchpoints for COVID-19 vaccines, on top of routine immunisation
- This grows to **~8 times** for first half of 2022 to reach 60% coverage of COVID-19 vaccination






Country by country qualitative analysis being undertaken to assess RI related risks as well as COVID-19 vaccination absorption

Illustrative countries

COVAX: Risk of low absorption of COVID-19 vaccines	High		 Nigeria  DRC  South Sudan	 PNG
	Medium			
	Low		 Kenya	 India
		Low	Medium	High
		Gavi 5.0: Pandemic impacts on routine immunisation and zero-dose agenda		

DTP1 change, 2015-19¹

-  Increase (> 1pp)
-  Stagnation (-1 to +1 pp)
-  Decrease (< -1pp)

¹ WUENIC 2021 release

Tailored engagement in each country to advance zero dose agenda along with COVID-19 vaccination

	Zero-dose (ZD) children			Pandemic impacts on RI		COVID-19 vaccine delivery		Gavi engagement on zero-dose
	2015	2019	2020	DTP3 2019 vs 2020 ¹	RI impact	% fully vaccinated	Absorption risk	
India	2.36	1.40	3.03	-6pp	●	15.5%	●	<ul style="list-style-type: none"> Tailored 2022-26 strategy for Dec 2021 Board meeting; \$129m in zero-dose
Pakistan	0.98	0.57	0.97	-7pp	●	10.2%	●	<ul style="list-style-type: none"> FPP (incl. EAF) to be submitted in Q1/22 ZD identification started, FPP workshops scheduled for Dec 2021
Nigeria	3.39	2.48	2.52	0pp	●	1.6%	●	<ul style="list-style-type: none"> Strong momentum at national, state and LGA level around zero-dose concept Development of ZD strategy under way
Ethiopia	0.85	0.83	0.84	+3pp	●	1.0%	●	<ul style="list-style-type: none"> FPP (incl. EAF) to be submitted in Q1/22 ZD identification started
DRC	1.01	1.13	1.15	0pp	●	0.09%	●	<ul style="list-style-type: none"> ZD targeted through Mashako plan Plan to access EAF as of Q2/22

¹ WUENIC 2021 release, percentage point difference

● Higher impact / risk

● Medium impact / risk

● Lower impact / risk

Zero dose agenda is beginning to be a key focus of all our funding levers



Equity Accelerator funding (EAF)

Country funding window opened (\$400m); ~8 applications anticipated in 2021
Multi-country initiative (\$100m); call for partnerships launched, short-listing underway



Health System Strengthening (HSS)

21 country FPPs in 2020-2021 with focus on equity and zero dose children; of these, 7 countries have made significant progress with clear prioritisation of zero-dose agenda



Campaigns

Specific strategies to reach missed communities. Mozambique and Ethiopia included geospatial mapping to identify communities in conflict-affected and hard-to-reach areas



PEF Targeted Country Assistance (TCA)

Pivoting towards TA focused on zero dose children and missed communities e.g. DRC, Ethiopia, Haiti, Nigeria, Pakistan, South Sudan, Yemen

Despite current challenges, missions have been undertaken in key countries

Multi-stakeholder dialogues in 55 countries over the past year



Nigeria

- Mission in Q2 2021 with state engagement
- Zero dose workshop and PHC summit
- Focus on RI and zero dose in different contexts
- COVAX and urban immunisation strategies
- Public financial management and accountability



Pakistan

- Mission planned in Q3 2021
- Planning for MR/OPV campaign and TCV phase 3
- FPP and EAF
- COVAX cost-sharing, NDVP update and CDS progress
- Potential refugee influx and Humanitarian Buffer



DRC

- Mission in Q2 2021, bilateral partner engagement
- Progress on the Mashako plan
- Advocacy for co-financing
- COVID-19 vaccination roll-out and impact



Papua New Guinea

- 2-month mission in Q2 2021
- COVID-19 vaccination roll-out and redeployment
- Promote RI catch-up and resolution of staffing gaps
- Engagement on next phase for Board strategy

Countries are continuing to leverage Gavi support



Independent Review Committee (IRC)

- **48 applications** for Gavi support in 2021; 92% recommended for approval representing **\$54m funding**
- **69 applications**, representing **\$46m**, recommended for approval for **COVAX CCE** in 2021
- **23 additional applications** anticipated for Gavi and COVAX support in remainder of 2021, totalling **~\$137m**



High Level Review Panel (HLRP)

- Vaccine programmes in **67 countries** reviewed in 2021, with **~440m vaccines doses**, representing **~\$890m**, recommended for approval
- **\$63m in programme renewals** recommended for approval in 2021 including HSS, CCEOP, and YF Diagnostic procurement



Partnerships Team (PT)

- **\$85m PEF TCA and \$58m COVAX TA** funding requests reviewed for 2021
- **>600 in-country partner staff** through PEF TCA and COVAX TA
- PT to review **~\$180m** for **FS and SFA** for 2022-2025
- PT reviewing stepped-up investments in **CSO initiative**



Int'l Coordinating Group (ICG)

- **9 requests** received for 2021, **13.4m doses** shipped to date
- **Lower number of ICG requests** in 2020 and 2021, primarily due to lower number of cholera and yellow fever requests.
- However, **highest number of cholera doses** expected to be shipped since creation of stockpile

Continued attention is being paid to Gavi 5.0 in line with recalibrated priorities

SG1: Introduce & scale-up vaccines

Vaccine introductions
completed year to date

2020	2021
5	6

Campaigns
conducted year to date

2020	2021
8	18

SG3: Improve sustainability

Co-financing obligations
% paid by 31 Aug

Ø 2019-20	2021
60%	61%

Co-financing waivers
approved

2020	2021 YTD
8	1 ¹

SG2: Strengthen health systems

FPP processes
started

2020	2021
11	10

TCA country plans
submitted by 31 Aug

2020	2021
57	56 ²

HSS disbursements
US\$, disbursed 31 Aug

2020	2021 YTD
\$225m	\$114m

SG4: Ensure healthy markets

Supply interruption
of routine vaccine supply interruptions owing to COVID-19

Jul 2020	Jul 2021
0	0

● Significant challenges / delays
 ● Some challenges / delays
 ● On track against objectives informed by recalibrated priorities

¹ Waiver for Pakistan approved in 2020 for the fiscal year 2020-21, as the disbursement takes place in 2021

² Kenya will separately submit a multi-year TCA plan as part of its FPP process

THANK YOU



www.gavi.org